MXCT - MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M
2024-01-08 16:36:57 ET
More on MaxCyte
- MaxCyte May Benefit From Potential Gene Therapy Approval
- MaxCyte announces departure of founder and CEO Doug Doerfler
- Gene editing stocks mixed despite world’s first CRISPR drug approval
- Seeking Alpha’s Quant Rating on MaxCyte
For further details see:
MaxCyte says Q4 revenue is expected to be between $15.5M and $15.7M